699
Views
2
CrossRef citations to date
0
Altmetric
Research Paper

Knockdown of miR-1275 protects against cardiomyocytes injury through promoting neuromedin U type 1 receptor

, , , , , & show all
Pages 3639-3649 | Received 06 Dec 2019, Accepted 02 Nov 2020, Published online: 15 Dec 2020

Figures & data

Figure 1. miR-1275 was upregulated in hESC-derived cardiomyocytes and H9C2 cardiomyocytes after treated by OGD/R. (a) The expression of specific cardiomyocyte markers (GATA4, TNNT2, and MYL7) and hESC-specific markers (Oct-4 and Sox-2) in hESC-derived cardiomyocytes was examined by western blotting. (b) Representative image of hESC-derived cardiomyocytes. (c and d) LDH activity of hESC-derived cardiomyocytes and H9C2 cardiomyocytes was measured after treated by oxygen-glucose deprivation (OGD) followed by reperfusion for 3 h, 6 h, 12 h, 24 h. (e and f) The expression of miR-1275 in cardiomyocytes was measured through RT-qPCR after stimulation by OGD/R treatment. Values are expressed as mean ± SEM, n = 3, *P < 0.05, **P < 0.01, compared with the untreated group. #P < 0.05, compared with the OGD + reperfusion for 3 h treatment group

Figure 1. miR-1275 was upregulated in hESC-derived cardiomyocytes and H9C2 cardiomyocytes after treated by OGD/R. (a) The expression of specific cardiomyocyte markers (GATA4, TNNT2, and MYL7) and hESC-specific markers (Oct-4 and Sox-2) in hESC-derived cardiomyocytes was examined by western blotting. (b) Representative image of hESC-derived cardiomyocytes. (c and d) LDH activity of hESC-derived cardiomyocytes and H9C2 cardiomyocytes was measured after treated by oxygen-glucose deprivation (OGD) followed by reperfusion for 3 h, 6 h, 12 h, 24 h. (e and f) The expression of miR-1275 in cardiomyocytes was measured through RT-qPCR after stimulation by OGD/R treatment. Values are expressed as mean ± SEM, n = 3, *P < 0.05, **P < 0.01, compared with the untreated group. #P < 0.05, compared with the OGD + reperfusion for 3 h treatment group

Figure 2. Knockdown of miR-1275 inhibited cell apoptosis and cell injury in cardiomyocytes with OGD/R treatment. (a) Transfection efficiency of miR-1275 antagomirs in hESC-derived cardiomyocytes was examined. miR-1275 antagomirs (40 nM, anta-miR) or negative control antagomir (40 nM, anta-NC) were transfected into hESC-derived cardiomyocytes and cultured for 48 h. *P < 0.05, **P < 0.01, compared with negative control group. (b) The expression of miR-1275 in OGD/R-stimulated cardiomyocytes was measured after transfected with miR-1275 antagomir1 (anta-miR). (c, d) LDH and CK activity in OGD/R-stimulated cardiomyocytes were analyzed by ELISA Kits. (e, f) Cell apoptosis was detected through the Annexin V-FITC/PI double staining kit. (g) The expression of apoptosis-related proteins was detected through Western blotting. (h-j) ROS levels (h), Intracellular Ca2+ concentration (i) and SR Ca2+ leak (j) in cardiomyocytes were tested. Values are expressed as mean ± SEM, n = 3, *P < 0.05, **P < 0.01, compared with untreated group; #P < 0.05, compared with OGD/R + anta-NC treated group

Figure 2. Knockdown of miR-1275 inhibited cell apoptosis and cell injury in cardiomyocytes with OGD/R treatment. (a) Transfection efficiency of miR-1275 antagomirs in hESC-derived cardiomyocytes was examined. miR-1275 antagomirs (40 nM, anta-miR) or negative control antagomir (40 nM, anta-NC) were transfected into hESC-derived cardiomyocytes and cultured for 48 h. *P < 0.05, **P < 0.01, compared with negative control group. (b) The expression of miR-1275 in OGD/R-stimulated cardiomyocytes was measured after transfected with miR-1275 antagomir1 (anta-miR). (c, d) LDH and CK activity in OGD/R-stimulated cardiomyocytes were analyzed by ELISA Kits. (e, f) Cell apoptosis was detected through the Annexin V-FITC/PI double staining kit. (g) The expression of apoptosis-related proteins was detected through Western blotting. (h-j) ROS levels (h), Intracellular Ca2+ concentration (i) and SR Ca2+ leak (j) in cardiomyocytes were tested. Values are expressed as mean ± SEM, n = 3, *P < 0.05, **P < 0.01, compared with untreated group; #P < 0.05, compared with OGD/R + anta-NC treated group

Figure 3. NMUR1 is a predicted target of miR-1275 and it is negatively regulated by miR-1275. (a) The miR-1275 seed sequences and the predicted binding sites of NMUR1 3ʹ-UTR mutation sites are highlighted in red. (b) Transfection efficiency of miR-1275 mimics in hESC-derived cardiomyocytes was examined. Negative control mimics (30 nM, mimic-NC) and miR-1275 mimics (30 nM, miR mimic) were transfected into hESC-derived cardiomyocytes and incubated for 48 h. (c) Luciferase activity of NMUR1 was tested. **P < 0.01, compared with NC mimic transfection group. (d) The expression of NMUR1 mRNA was examined. Values are expressed as mean ± SEM, n = 3, **P < 0.01, compared with untreated group. #P < 0.05, compared with mimic-NC transfected group; &P < 0.05, compared with anta-NC transfected group

Figure 3. NMUR1 is a predicted target of miR-1275 and it is negatively regulated by miR-1275. (a) The miR-1275 seed sequences and the predicted binding sites of NMUR1 3ʹ-UTR mutation sites are highlighted in red. (b) Transfection efficiency of miR-1275 mimics in hESC-derived cardiomyocytes was examined. Negative control mimics (30 nM, mimic-NC) and miR-1275 mimics (30 nM, miR mimic) were transfected into hESC-derived cardiomyocytes and incubated for 48 h. (c) Luciferase activity of NMUR1 was tested. **P < 0.01, compared with NC mimic transfection group. (d) The expression of NMUR1 mRNA was examined. Values are expressed as mean ± SEM, n = 3, **P < 0.01, compared with untreated group. #P < 0.05, compared with mimic-NC transfected group; &P < 0.05, compared with anta-NC transfected group

Figure 4. Silence of NMUR1 reversed the effect of miR-1275 knockdown on cell injury in myocardial cell. (a, b) The expression of NMUR1 mRNA and proteins in cardiomyocytes was measured after transfection with si-NMUR1 (50 nM). **P < 0.01, compared with si-NC transfected group. (c–h) NMUR1 expression (c), LDH (e) and CK (f) activity, ROS levels (F) and cell apoptosis (g, h) in cardiomyocytes were detected after transfection with the miR-1275 antagomir, si-NMUR1 or co-transfection with the miR-1275 antagomir and si-NMUR1. Values are expressed as mean ± SEM, n = 3, *P < 0.05, **P < 0.01, compared with untreated group. #P < 0.05, compared with OGD/R-treated group; &P < 0.05, compared with OGD/R + anta-miR transfected group

Figure 4. Silence of NMUR1 reversed the effect of miR-1275 knockdown on cell injury in myocardial cell. (a, b) The expression of NMUR1 mRNA and proteins in cardiomyocytes was measured after transfection with si-NMUR1 (50 nM). **P < 0.01, compared with si-NC transfected group. (c–h) NMUR1 expression (c), LDH (e) and CK (f) activity, ROS levels (F) and cell apoptosis (g, h) in cardiomyocytes were detected after transfection with the miR-1275 antagomir, si-NMUR1 or co-transfection with the miR-1275 antagomir and si-NMUR1. Values are expressed as mean ± SEM, n = 3, *P < 0.05, **P < 0.01, compared with untreated group. #P < 0.05, compared with OGD/R-treated group; &P < 0.05, compared with OGD/R + anta-miR transfected group

Figure 5. Silence of NMUR1 partly suppressed the inhibitory effect of miR-1275 knockdown on calcium overload in OGD/R in hESC-derived cardiomyocytes. (a, b). Intracellular Ca2+ concentration and SR Ca2+ leak in cardiomyocytes were examined. (c, d). The expressions of NMUR1, NCX1, RyR2, SERCA2a, PS16 PLN, and total-PLN (t-PLN) were examined by Western blot analysis. Values are expressed as mean ± SEM, n = 3, *P < 0.05, **P < 0.01, compared with untreated group. #P < 0.05, compared with OGD/R-treated group; &P < 0.05, compared with OGD/R + anta-miR transfected group

Figure 5. Silence of NMUR1 partly suppressed the inhibitory effect of miR-1275 knockdown on calcium overload in OGD/R in hESC-derived cardiomyocytes. (a, b). Intracellular Ca2+ concentration and SR Ca2+ leak in cardiomyocytes were examined. (c, d). The expressions of NMUR1, NCX1, RyR2, SERCA2a, PS16 PLN, and total-PLN (t-PLN) were examined by Western blot analysis. Values are expressed as mean ± SEM, n = 3, *P < 0.05, **P < 0.01, compared with untreated group. #P < 0.05, compared with OGD/R-treated group; &P < 0.05, compared with OGD/R + anta-miR transfected group
Supplemental material

Supplemental Material

Download MS Word (536.6 KB)

Data availability

The data used to support the findings of this study are included within the article.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.